Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
157 hedge funds and large institutions have $803M invested in Esperion Therapeutics in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 52 reducing their positions, and 26 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 52
2.93% less ownership
Funds ownership: 113.7% → 110.77% (-2.9%)
5% less funds holding
Funds holding: 166 → 157 (-9)
23% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $15.1M
32% less capital invested
Capital invested by funds: $1.18B → $803M (-$373M)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$47.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.6M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$20.9M |
| 4 |
Morgan Stanley
New York
|
+$6.01M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$50.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$27.3M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$14.6M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
-$14.2M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$9.8M |
ESPR Hedge Fund Activity: Q4 2020 in Review
157 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2020, worth a combined $803M — down 32% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ESPR and 17 opened new positions — a net loss of 9 holders — while 52 trimmed existing stakes and 52 added.
The largest buyer was Wasatch Advisors, adding an estimated $47.6M. The largest seller was Pentwater Capital Management, cutting an estimated $50.1M.
- 157 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2020, down from 166 in Q3 2020.
- Funds reported $803M of Esperion Therapeutics stock for Q4 2020, down 32% quarter-over-quarter.
- 17 funds opened new Esperion Therapeutics positions in Q4 2020 and 26 closed out, a net change of -9 holders.
- The largest Esperion Therapeutics buyer in Q4 2020 was Wasatch Advisors, an estimated $47.6M added.
- The largest Esperion Therapeutics seller in Q4 2020 was Pentwater Capital Management, an estimated $50.1M sold.
Based on aggregated 13F filings for Q4 2020.